Elicio Therapeutics(ELTX) - 2023 Q1 - Quarterly Report

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number 001-39990 Washington, D.C. 20549 _____________________________________________ ANGION BIOMEDICA CORP FORM 10-Q _____________________________________________ (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...